Gland Pharma reported a 47% rise in Q1 fiscal 2027 net profit to ₹317 crore, driven by a 20% revenue increase from its CDMO segment. While year-on-year growth remains strong, the company faced a 14% sequential profit decline due to curre...
Mumbai-based Lilavati Hospital will launch a super-speciality outpatient department (OPD) in Kazakhstan in early September 2026. This facility aims to provide medical consultations and treatment planning, acting as a referral conduit to...
Wockhardt plans to launch its US FDA-approved antibiotic, Zaynich, in the US by early 2027, with European approval expected soon. The company also reported a net profit of ₹107 crore for the June 2026 quarter, a turnaround from the loss...
Wockhardt Limited launched its 'Antibiotic Academy' for antimicrobial research while reporting a Q1 FY27 profit of ₹107 crore, turning around from a loss last year. Despite revenue growth to ₹929 crore, the company's stock fell 4.44% on...
Motilal Oswal has maintained a 'Neutral' rating on Lupin Limited with a price target of ₹2,500. While the company beat Q1FY27 expectations, the brokerage reduced its profit estimates by 6% due to higher tax and depreciation costs. Invest...
Lupin has received US FDA approval for its generic hyperkalemia treatment, a significant move for its US product pipeline. While the company reported strong Q1 FY2027 revenue and profit growth, the stock faced selling pressure as investo...
Wockhardt Ltd posted a consolidated net profit of ₹107 crore for the first quarter of FY27, turning around from a loss of ₹108 crore in the same period last year. Revenue climbed 26% to ₹929 crore. Despite the positive results, the stock...
Molbio Diagnostics’ initial public offering (IPO) launched for subscription on August 10, 2026, targeting a total raise of approximately ₹940 crore. The offer, which includes a fresh issue and offer for sale, runs until August 12. Invest...
The initial public offering of Molbio Diagnostics is now open for subscription from August 10 to August 12, 2026, with a price band of ₹768–₹807 per share. While brokerage Anand Rathi has issued a 'subscribe' rating for long-term investo...
Ipca Laboratories shares dipped 2% to Rs 1,701 on Monday morning amid recent volatility. Investors are now shifting their focus toward the company's first-quarter financial results and its 76th Annual General Meeting, both scheduled for...